|
|
|
|
|
|
|
|
|
02.04.26 - 12:06
|
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability (Business Wire)
|
|
|
Med Tech segment delivered its sixth consecutive quarter of double-digit growth
Strong adjusted EBITDA
Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted EBITDA
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026.
Fiscal Year 2026 Third Quarter Highlights
Quarter Ended
February 28, 2026
Pro Forma* YoY Growth
Net Sales
$78.4 million
8.9%
Med Tech Net Sales
$37.3 million
19.0%
Med Device Net Sales
$41.1 million
1.1%
GAAP gross margin of 52.9%
GAAP loss per share of $0.19
Adjusted loss per share of $0.07
Adjusted EBITDA of $1.8 million
Ended fiscal 2026 third quarter with $37.8 million in cash, in line with expectation...
|
|
|
|
|
|
|
19.03.26 - 13:06
|
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026 (Business Wire)
|
|
|
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available, until Thursday, April 9, 2026 at 11:59 PM ET. To hear this recording, dial 1-84...
|
|
|
|
|
|
|
|
|
|
|
|
|
05.02.26 - 14:03
|
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care (Business Wire)
|
|
|
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE EvidenceLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, and The PERT Consortium®, a leading multidisciplinary organization dedicated to improving pulmonary embolism (PE) care, today announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent PE research.
Pulmonary embolism affects approximately one in 1,000 people annually1. It is estimated to contribute to more than 50,000 deaths each year in the United States,2 underscoring the need for continued clinical research and innovation.
The ALPHA-PE Research Fund is designed to support independent, physician-led research addressing critical evidence gaps in pulmonary embolism care, where a lack of real-...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
